Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 3/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2392652 | 0.89 | PPARG (0.44) | CCR2SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL2395176 | 0.81 | LMNA (0.45) | CCR2GAAPOLBL3MBTL1KDM4E | |
| SCHEMBL2398375 | 0.77 | L3MBTL1 (0.43) | CCR2SLC6A4KCNH2GAAPOLB | |
| SCHEMBL2393320 | 0.74 | PTGDR2 (0.47) | CCR2GAAPOLBPTGDR2L3MBTL1 | |
| SCHEMBL2395020 | 0.72 | GAA (0.43) | SLC6A2SLC6A4SLC6A3GAAPOLB | |
| SCHEMBL2391634 | 0.72 | PTGDR2 (0.47) | CCR2GAAPTGDR2KDM4EHTT | |
| SCHEMBL24460021 | 0.72 | ALDH1A1 (0.56) | GAAPOLBKDM4EHTTHPGD | |
| SCHEMBL5866714 | 0.70 | MAPT (0.59) | CCR2GAAPOLBL3MBTL1HTT | |
| SCHEMBL2396776 | 0.69 | LMNA (0.48) | GAAPOLBKDM4E | |
| SCHEMBL4577297 | 0.69 | HPGD (0.63) | POLBIDH1KDM4EHTTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022248-B2 | 3-[2-(3-Cyanophenoxy)-4-(trifluoromethyl)phenyl]propanoic acid;prostaglandin D2 inhibitor, orphan receptor CRTH2 antagonist; antiinflammatory, analgesic, antipyretic; respiratory system disorders: asthma and rhinitis; coupling amino/thio-phenyl derivatives with ester followed by hydrolysis to acid | ASTRAZENECA AB (SE) | 2011-09-20 | — | — | US | disclosed |
| US-20080114002-A1 | Substituted Acids for the Treatment of Respiratory Diseases | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114002-A1 | Substituted Acids for the Treatment of Respiratory Diseases | HRH2, HRH1, HRH4 | CCR2 1327/4885SLC6A2 1555/4885SLC6A4 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.